Trevi Therapeutics Q2 net loss widens on higher R&D costs

Trevi Therapeutics

06/08/2026 21:18

Overview
US biopharmaceutical firm's Q2 net loss widened yr/yr amid higher R&D and G&A expenses
Company ended Q2 with $318.9 mln in cash, boosted by April stock offering
Cash runway expected to extend into 2030, supporting ongoing and planned clinical trials

Outlook
Company expects to initiate Phase 3 OCEAN-2 trial in IPF-related chronic cough in Q3 2026
Topline results from Phase 2b LAKE trial in RCC expected in H2 2027
Company expects current cash to fund operations into 2030, excluding commercial launch costs

Result Drivers
CLINICAL TRIAL SPENDING - Higher R&D expenses driven by increased clinical development costs for Phase 3 OCEAN-1, Phase 2b LAKE, Phase 3 OCEAN-2 trials and Phase 1 studies
HIGHER ADMINISTRATIVE COSTS - G&A expenses rose due to increased stock-based compensation and personnel costs
INCREASED INTEREST INCOME - Other income rose due to higher interest income from larger cash and marketable securities balances

Company press release: ID:nGNXbhM5Zy

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$0.11
 
Q2 Net Loss
 
$17.80 mln
 
Q2 Income from Operations
 
-$20.51 mln
 
Q2 Operating Expenses
 
$20.51 mln
 
Q2 Pretax Loss
 
$17.82 mln
 

Reuters Recommended Reads
Aug 6 - vTv Therapeutics Q2 net loss widens on higher trial costs
Aug 6 - Compass Therapeutics Q2 net loss widens on higher R&D and G&A costs
Aug 6 - Ireland's GH Research Q2 net loss widens on higher R&D costs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)